{
    "2019-08-13": [
        [
            {
                "time": "2019-08-14",
                "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for August 14, 2019",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Ex-Dividend",
                        "Date",
                        "Scheduled"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-08-14",
                "original_text": "8 Stocks That Have Paid a Dividend for 125 (or More) Consecutive Years",
                "features": {
                    "keywords": [
                        "Stocks",
                        "Dividend",
                        "Consecutive",
                        "Years"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-14",
                "original_text": "Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Taltz",
                        "Superiority",
                        "Trial",
                        "Psoriasis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-08-14",
                "original_text": "How one Boston startup rode the diabetes investment wave to raise $126M",
                "features": {
                    "keywords": [
                        "Boston",
                        "startup",
                        "diabetes",
                        "investment",
                        "wave",
                        "$126M"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-08-14",
                "original_text": "Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Psoriasis",
                        "Drug",
                        "Superior",
                        "Phase 4",
                        "Study"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}